

RECEIVED  
CENTRAL FAX CENTER

DEC 11 2006

## FAX TRANSMISSION

DATE: December 11, 2006

PTO IDENTIFIER: Application Number 10/680,459-Conf. #4494  
Patent Number

Inventor: Chris Rundfeldt et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: FULBRIGHT & JAWORSKI L.L.P.

Norman D. Hanson

PHONE: (212) 318-3168

Attorney Dkt. #: NY-HUBR 1230-US (10312533)

PAGES (including Cover Sheet): 4

CONTENTS: Response to Restriction Requirement (with Traverse) (2 pages)  
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (212) 318-3168 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue, New York, New York 10103  
Telephone: (212) 318-3000 Facsimile: (212) 318-3400

RECEIVED  
CENTRAL FAX CENTER

DEC 11 2006

Docket No.: NY-HUBR 1230-US  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Chris Rurdfeldt et al.

Application No.: 10/680,459

Confirmation No.: 4494

Filed: October 6, 2003

Art Unit: 1617

For: USE OF DIHYDROIMIDAZOLONES FOR  
THE TREATMENT OF DOGS

Examiner: D. R. Claytor

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement set forth in the Office Action mailed November 24, 2006, applicant hereby elects Group I, claims 12-19.

This election is made with traverse.

The Examiner states the inventions are not related. Applicants believe the record shows that they are. Indeed the restriction points out:

- (i) the same compound is used in both groups;
- (ii) the inventions are classified identically.

Hence, in a search for uses of 1-(4-chlorophenyl)-4-(4-morpholinyl)2,5-dihydro-1H-imidazol-1-yl one will *de facto* find art relating to each of the inventions. No undue search burden is seen.

25725465.1

Application No.: 10/680,459

Docket No.: NY-HUBR 1230-US

Further, the claims in allegedly separate invention II are drawn to behavioral abnormalities generally. While there is a specific claim to anxiety, the statement that:

"the different inventions are drawn to treatment of epilepsy... and the treatment of behavioral abnormalities, namely anxiety."

(emphasis added) misstates the claim structure. A generic claim to behavioral abnormalities is presented, of which epilepsy is an example. This is admitted by the Examiner, who states:

"Epilepsy is characterized by involuntary change in body movement or function, sensation awareness or behavior."

"Involuntary changes in behavior" is a behavioral abnormality. Focusing on the specific claim to anxiety, as the Examiner has, does not correctly address the claims.

In view of the foregoing, withdrawal of the restriction and consideration of all claims is believed proper and is urged.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 50-0624, under Order No. NY-HUBR 1230-US (10312533) from which the undersigned is authorized to draw.

Dated: December 11, 2006

Respectfully submitted,

By 

Norman D. Hanson

Registration No.: 30,946

FULBRIGHT & JAWORSKI L.L.P.

666 Fifth Avenue

New York, New York 10103

(212) 318-3000

(212) 318-3400 (Fax)

Attorney for Applicant

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/680,459

Attorney Docket No.: NY-HUBR 1230-US

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on December 11, 2006  
Date



Signature

Fani Malikouzakis

Typed or printed name of person signing Certificate

Registration Number, if applicable

(212) 318-3220  
Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Response to Restriction Requirement (with Traverse) (2 pages)

25725470.1

2